Lehner T, Wilton J M, Ivanyi L
Lancet. 1976 Oct 30;2(7992):926-9. doi: 10.1016/s0140-6736(76)90891-6.
A double blind crossover trial of levamisole has been carried out in 47 patients with recurrent oral ulceration. Significant decreases in the number of ulcers and ulcer days were found after 2 months of intermittent administration of levamisole. About 64% of patients responded to the drug by a decrease in the number of ulcers of more than 50%, for two or more months. The remaining 36% of patients failed to respond to levamisole and 23% of these had an increased number of ulcers. The side-effects recorded in patients taking levamisole were comparable with those in patients on placebo, except for a flu-like syndrome in 1 patient and urticaria in another, necessitating withdrawal of the drug. The mechanism of action of levamisole in recurrent oral ulceration is not known, but it is suggested that levamisole may correct a deficiency of suppressor cells, or potentiate the cellular responses to crossreacting microbial agents.
对47例复发性口腔溃疡患者进行了左旋咪唑双盲交叉试验。在间歇性服用左旋咪唑2个月后，发现溃疡数量和溃疡天数显著减少。约64%的患者对该药有反应，溃疡数量减少超过50%，持续两个月或更长时间。其余36%的患者对左旋咪唑无反应，其中23%的患者溃疡数量增加。服用左旋咪唑的患者记录的副作用与服用安慰剂的患者相当，只是有1例出现类似流感的综合征，另1例出现荨麻疹，需要停药。左旋咪唑在复发性口腔溃疡中的作用机制尚不清楚，但有人认为左旋咪唑可能纠正抑制细胞的缺陷，或增强细胞对交叉反应微生物制剂的反应。
